Drug Type CAR-NK |
Synonyms CYT 538, CYT-538 |
Target |
Mechanism CD38 modulators(Lymphocyte differentiation antigen CD38 modulators), Immunologic cytotoxicity, Natural killer cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lymphoma | Preclinical | US | Cytovia Therapeutics, Inc.Startup | 10 Nov 2020 |
Lymphoma | Preclinical | FR | 10 Nov 2020 | |
Multiple Myeloma | Preclinical | US | Cytovia Therapeutics, Inc.Startup | 10 Nov 2020 |
Multiple Myeloma | Preclinical | FR | 10 Nov 2020 |